Open AccessDissertation
Growth factor activation of ErbB2/ErbB3 signaling pathways regulate the activity of Estrogen Receptors (ER)
Melanie Sanchez
- 04 Nov 2010
4
TL;DR: The results presented were carried out with the objective of gaining a better understanding of ERβ’s role in cellular proliferation by examining the behavior of ER β and ERα during the activation of growth factor signaling pathways by cell-surface receptor-tyrosine kinases.
read more
Abstract: It has long been appreciated that estrogenic signaling plays a critical role in the development of hormone-dependent cancers such as breast cancer. Two-thirds of breast cancers express estrogen receptor (ER) which has been demonstrated to play an irrefutable role in tumour development and progression. However the acquisition of endocrine resistance has become a major obstacle in the treatment of hormone-dependent cancers that have acquired a hormone-independent state. Hormone-independent cancers emerge from an array of pathways involving ER activation in the absence of estrogen, hypersensitivity of ER to low serum levels of estrogen and activation by estrogen antagonists. The activity of ER is critically influenced by the cellular environment such as growth factor signaling pathways, availability of coregulatory proteins and the promoter sequence of target genes. The mechanisms studied have mostly considered the role of ERα, however with the discovery of the second subtype, ERβ, the understanding on the diversity of potential mechanisms involving ER-dependent responses have improved. Hormonal-independent activation of ER can occur in estrogendependent breast tumours, with concomitant rise in kinase signaling pathways, resulting in the acquisition of a therapeutic resistant phenotype in treated women. Our knowledge is relatively limited on which pathways trigger ER signaling and how these phosphorylationcoupled events affect ER activity. ERα is considered the dominant subtype and correlates with most of the prognostic factors in breast cancers. Conversely the role of ERβ remains unclear. The results presented in this thesis were carried out with the objective of gaining a better understanding of ERβ’s role in cellular proliferation by examining the behavior of ERβ and ERα during the activation of growth factor signaling pathways by cell-surface receptor-tyrosine kinases.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Acetylation and phosphorylation cooperate to regulate the degradation of active GATA-1
TL;DR: It is shown here that acetylated GATA-1 is targeted for degradation via the ubiquitin/proteasome pathway, suggesting that activation by acetylation simultaneously marks GATA, the key haemopoietic transcription factor, for degradation.
61
Effect of estrogen plus progestin on stroke in postmenopausal women: The Women's Health initiative: A randomized trial
Sylvia Wassertheil-Smoller,Susan L. Hendrix,Marian C. Limacher,Gerardo Heiss,Charles Kooperberg,Alison E. Baird,Theodore A. Kotchen,J. David Curb,Henry R. Black,Jacques E. Rossouw,Aaron K. Aragaki,Monika M. Safford,Evan A. Stein,Somchai Laowattana,W. Jerry Mysiw +14 more
TL;DR: Excess risk for all strokes attributed to estrogen plus progestin appeared to be present in all subgroups of women examined, and excess risk of all stroke was apparent in all age groups, in all categories of baseline stroke risk, and in women with and without hypertension, prior history of cardiovascular disease, use of hormones, statins, or aspirin.
References
Opposite effects of estrogen receptors alpha and beta on MCF-7 sensitivity to the cytotoxic action of TNF and p53 activity
Sebastian A. Lewandowski,Jerome Thiery,Abdelali Jalil,Guy Leclercq,Cezary Szczylik,Salem Chouaib +5 more
TL;DR: The studies suggest that estrogen-induced MCF-7 cell survival in the presence of TNF requires a transcriptionally active p53 and indicate that introduction of ERβ can attenuate the estrogen effects on the p53 protein location, its transcriptional activity and also results in a potentiation of cell sensitivity to TNF-mediated cell death.
39
Estrogen receptor-beta mediates cyclooxygenase-2 expression and vascular prostanoid levels in human placental villous endothelial cells
TL;DR: ESR2 mediates COx-2 expression levels and both prostacyclin and thromboxane concentrations in the basal state, which suggests the possibility of ligand-independent regulation of COX-2 activity and prostaglandin H2 substrate availability.
38
ARDent about acetylation and deacetylation in hypoxia signalling.
Rebecca L. Bilton,Rebecca L. Bilton,Eric Trottier,Jacques Pouysségur,M. Christiane Brahimi-Horn +4 more
TL;DR: The observation that small-molecule inhibitors of HDACs have anti-angiogenic activity suggests that acetylation and deacetylation of HIF or HIF modifiers represents a potential target in cancer therapy.
35
Clinicopathological Characteristics of Estrogen Receptor- β-positive Human Breast Cancers
TL;DR: Determining ER‐β status might be clinically useful for further defining the characteristics of ER‐α‐positive tumors is suggested.
34
Tamoxifen and the farnesyl transferase inhibitor FTI-277 synergize to inhibit growth in estrogen receptor-positive breast tumor cell lines.
Chad A. Ellis,Michele D. Vos,Meredith Wickline,Christine Riley,Teresa Vallecorsa,William G. Telford,JoAnne Zujewski,Geoffrey J. Clark +7 more
TL;DR: It is shown that anti-estrogens and an FTI (FTI-277) synergize to inhibit cell growth and enhance cell death in ER positive, human breast tumor cell lines.
33